Table of Contents
ISRN Endocrinology
Volume 2013 (2013), Article ID 184753, 5 pages
http://dx.doi.org/10.1155/2013/184753
Research Article

Liraglutide Suppresses the Plasma Levels of Active and Des-Acyl Ghrelin Independently of Active Glucagon-Like Peptide-1 Levels in Mice

Department of Lifestyle Medicine, Translational Research Center, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan

Received 23 June 2013; Accepted 14 July 2013

Academic Editors: O. Giampietro and P. Morosini

Copyright © 2013 Katsunori Nonogaki and Marina Suzuki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Nonogaki, “Ghrelin and feedback systems,” Vitamins and Hormones, vol. 77, pp. 149–170, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. D. L. Williams, H. J. Grill, D. E. Cummings, and J. M. Kaplan, “Vagotomy dissociates short- and long-term controls of circulating ghrelin,” Endocrinology, vol. 144, no. 12, pp. 5184–5187, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. J. J. Holst, “The physiology of glucagon-like peptide 1,” Physiological Reviews, vol. 87, no. 4, pp. 1409–1439, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. J. A. Lovshin and D. J. Drucker, “Incretin-based therapies for type 2 diabetes mellitus,” Nature Reviews Endocrinology, vol. 5, no. 5, pp. 262–269, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. R. Hayes, B. C. de Jonghe, and S. E. Kanoski, “Role of the glucagon-like-peptide-1 receptor in the control of energy balance,” Physiology and Behavior, vol. 100, no. 5, pp. 503–510, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Carrel, L. Egli, C. Tran et al., “Contributions of fat and protein to the incretin effect of a mixed meal,” American Journal of Clinical Nutrition, vol. 94, no. 4, pp. 997–1003, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Lippl, F. Kircher, J. Erdmann, H.-D. Allescher, and V. Schusdziarra, “Effect of GIP, GLP-1, insulin and gastrin on ghrelin release in the isolated rat stomach,” Regulatory Peptides, vol. 119, no. 1-2, pp. 93–98, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Hagemann, J. J. Holst, A. Gethmann, M. Banasch, W. E. Schmidt, and J. J. Meier, “Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion,” Regulatory Peptides, vol. 143, no. 1–3, pp. 64–68, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. D. J. Drucker, A. Dritselis, and P. Kirkpatrick, “Liraglutide,” Nature Reviews Drug Discovery, vol. 9, no. 4, pp. 267–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Nonogaki, M. Suzuki, M. Sanuki, M. Wakameda, and T. Tamari, “The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liragultide, a glucagon-like peptide 1 receptor agonist, in mice,” Biochemical and Biophysical Research Communications, vol. 411, no. 2, pp. 445–448, 2011. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Nonogaki, K. Nozue, and Y. Oka, “Hyperphagia alters expression of hypothalamic 5-HT2C and 5-HT1B receptor genes and plasma des-acyl ghrelin levels in Ay mice,” Endocrinology, vol. 147, no. 12, pp. 5893–5900, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Nagamatsu, M. Ohara-Imaizumi, Y. Nakamichi, K. Aoyagi, and C. Nishiwaki, “DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice β cells,” Biochemical and Biophysical Research Communications, vol. 412, no. 4, pp. 556–560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. G. M. E. Hussein, H. Matsuda, S. Nakamura et al., “Mate tea (Ilex paraguariensis) promotes satiety and body weight lowering in mice: involvement of glucagon-like peptide-1,” Biological and Pharmaceutical Bulletin, vol. 34, no. 12, pp. 1849–1855, 2011. View at Google Scholar · View at Scopus
  14. P. J. Larsen, C. Fledelius, L. B. Knudsen, and M. Tang-Christensen, “Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats,” Diabetes, vol. 50, no. 7–12, pp. 2530–2539, 2001. View at Google Scholar · View at Scopus
  15. K. J. Griffioen, R. Wan, E. Okun et al., “GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons,” Cardiovascular Research, vol. 89, no. 1, pp. 72–78, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. S. E. Kanoski, S. M. Fortin, M. Arnold, H. J. Grill, and M. R. Hayes, “Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4,” Endocrinology, vol. 152, no. 8, pp. 3103–3112, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. T. P. Vahl, M. Tauchi, T. S. Durler et al., “Glucagon-Like Peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats,” Endocrinology, vol. 148, no. 10, pp. 4965–4973, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. E. M. Sisson, “Liraglutide: clinical pharmacology and considerations for therapy,” Pharmacotherapy, vol. 31, no. 9, pp. 896–911, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. M. R. Hayes, S. E. Kanoski, B. C. de Jonghe et al., “The common hepatic branch of the vagus is not required to mediate the glycemic and food intake suppressive effects of glucagon-like-peptide-1,” American Journal of Physiology—Regulatory Integrative and Comparative Physiology, vol. 301, no. 5, pp. R1479–R1485, 2011. View at Publisher · View at Google Scholar · View at Scopus